Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Paul C. Hendrie"'
Autor:
Colin D. Godwin, Eduardo Rodríguez-Arbolí, Megan Othus, Anna B. Halpern, Jacob S. Appelbaum, Mary-Elizabeth M. Percival, Paul C. Hendrie, Vivian G. Oehler, Siobán B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Elihu H. Estey, Roland B. Walter
Publikováno v:
Cancers, Vol 14, Iss 12, p 2934 (2022)
Gemtuzumab ozogamicin (GO) improves outcomes when added to intensive AML chemotherapy. A meta-analysis suggested the greatest benefit when combining fractionated doses of GO (GO3) with 7 + 3. To test whether GO3 can be safely used with high intensity
Externí odkaz:
https://doaj.org/article/5ecb8885b7d247339f2c1d0b2022140f
Autor:
Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole Shaw, Anna B. Halpern, Pamela S. Becker, Paul C. Hendrie, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Publikováno v:
Haematologica, Vol 106, Iss 8 (2020)
Few patients with cancer, including those with acute myeloid leukemia and high-grade myeloid neoplasms, participate in clinical trials. Broadening standard eligibility criteria may increase clinical trial participation. In this retrospective single-c
Externí odkaz:
https://doaj.org/article/0395b57df88646eda61744ee5d03ecfc
Autor:
Anna B. Halpern, Megan Othus, Emily M. Huebner, Bart L. Scott, Paul C. Hendrie, Mary-Elizabeth M. Percival, Pamela S. Becker, Heather A. Smith, Vivian G. Oehler, Johnnie J. Orozco, Ryan D. Cassaday, Kelda M. Gardner, Tara L. Chen, Sarah A. Buckley, Kaysey F. Orlowski, Asma Anwar, Elihu H. Estey, Roland B. Walter
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
Externí odkaz:
https://doaj.org/article/f4c60eaa187e447a9c5cf66831e4bbbf
Autor:
Roland B. Walter, Megan Othus, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, Pamela S. Becker, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bruno C. Medeiros, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey
Publikováno v:
Haematologica, Vol 103, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/b050983645dc49d4893f684b474b0d2c
Autor:
Wei-Gang Tong, Vicky K. Sandhu, Brent L. Wood, Paul C. Hendrie, Pamela S. Becker, John M. Pagel, Roland B. Walter, Elihu H. Estey
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Externí odkaz:
https://doaj.org/article/3227802721044e28a4b8006c7a580e8a
Autor:
Roland B. Walter, Bruno C. Medeiros, Kelda M. Gardner, Kaysey F. Orlowski, Leonel Gallegos, Bart L. Scott, Paul C. Hendrie, Elihu H. Estey
Publikováno v:
Haematologica, Vol 99, Iss 1 (2014)
Epigenetic therapeutics such as the histone deacetylase inhibitor, vorinostat, and the DNA methyltransferase I inhibitor, azacitidine, enhance gemtuzumab ozogamicin efficacy in vitro. We therefore investigated vorinostat/azacitidine/gemtuzumab ozogam
Externí odkaz:
https://doaj.org/article/a48e037ac1f5450fa9441987e9993b83
Autor:
Ryan D. Cassaday, Lucas C. Zarling, Kelsey-Leigh A. Garcia, Olga Sala-Torra, Philip A. Stevenson, Christen H. Martino, Yajuan J. Liu, Min Fang, Mary-Elizabeth M. Percival, Anna B. Halpern, Pamela S. Becker, Vivian G. Oehler, Andrei R. Shustov, Jason P. Cooper, Johnnie J. Orozco, Paul C. Hendrie, Roland B. Walter, Jerald P. Radich, Lorinda A. Soma, Elihu H. Estey
Publikováno v:
Leukemia & Lymphoma. :1-11
Autor:
Michelle Y. Zhang, Megan Othus, Carole Shaw, Kelda G. Schonhoff, Anna B. Halpern, Jacob Appelbaum, Paul C. Hendrie, Roland B. Walter, Elihu H. Estey, Mary-Elizabeth M. Percival
Publikováno v:
Leukemia & Lymphoma. :1-7
Publikováno v:
Annals of Hematology. 102:1613-1615
Autor:
Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson, Nathalie Vigneron, Denise Buenrostro, Felecia D. Wagener, Valentin Voillet, Lauren Martin, Raphael Gottardo, Jason Bielas, Julie M. McElrath, Derek L. Stirewalt, Era L. Pogosova-Agadjanyan, Cecilia C. Yeung, Robert H. Pierce, Daniel N. Egan, Merav Bar, Paul C. Hendrie, Sinéad Kinsella, Aesha Vakil, Jonah Butler, Mary Chaffee, Jonathan Linton, Megan S. McAfee, Daniel S. Hunter, Marie Bleakley, Anthony Rongvaux, Benoit J. Van den Eynde, Aude G. Chapuis, Philip D. Greenberg
Publikováno v:
Sci Transl Med
Science translational medicine, Vol. 14, no.631, p. eabg8070 (2022)
Science translational medicine, Vol. 14, no.631, p. eabg8070 (2022)
Designing effective antileukemic immunotherapy will require understanding mechanisms underlying tumor control or resistance. Here, we report a mechanism of escape from immunologic targeting in an acute myeloid leukemia (AML) patient, who relapsed 1 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ab8910054866ad4b7f3c2247308f44
https://doi.org/10.1126/scitranslmed.abg8070
https://doi.org/10.1126/scitranslmed.abg8070